- Login
- Register & Subscribe
- Language: EN FR DE
Sunday 8 August 2010
Galápagos NV has paid an undisclosed sum to GlaxoSmithKline Plc to re-acquire rights to a candidate drug for rheumatoid arthritis which inhibits a family of enzymes known as Janus kinase (JAK). It will start a Phase 1 study on 9 August.
Country: Belgium
Friday 6 August 2010
A new preclinical antibiotic that is being developed by GlaxoSmithKline Plc has been shown in an image fighting bacteria that are resistant to conventional antibiotics.
Country: United Kingdom
Thursday 5 August 2010
Novo Nordisk A/S has estimated that sales will grow by 9 to 10% in 2010 based on continued market penetration of its core diabetes products and its new glucagon-like peptide-1 receptor agonist for Type 2 diabetes, Victoza (liraglutide).
Country: Denmark
Thursday 5 August 2010
GlaxoSmithKline Plc has agreed to pay $23 million upfront for exclusive access to technology developed by Amplimmune Inc of the US for potential therapies for cancer and other diseases. Specifically, GSK will obtain rights to a molecule targeting the membrane protein, PD-1.
Country: United Kingdom
Wednesday 4 August 2010
Shire Plc expects to increase its spending on research and development this year, even as it prepares to commit €428 million to complete its latest acquisition- an all-cash offer for Movetis NV of Belgium.
Country: Ireland
Wednesday 4 August 2010
Wilex AG has announced the successful completion of a rights issue which has raised €10 million in new money. The proceeds will be used to finance the ongoing clinical development of the company’s oncology portfolio.
Country: Germany
Wednesday 4 August 2010
With a debt restructuring completed and its core products booking substantial revenue gains in the first half, UCB SA has confirmed its forecast for 2010 revenue of €3 billion and a profit of €700 million.
Country: Belgium
Tuesday 3 August 2010
Shire Plc has announced a tender offer for the recently-listed Belgian company, Movetis NV, which has a product for chronic constipation on markets in the European Union. Shire is offering €19 per share in cash for Movetis, representing a premium of 74% to Movetis’s closing price on NYSE Euronext Brussels on 2 August 2010.
Country: Ireland
Tuesday 3 August 2010
Sanofi-Aventis SA has reportedly offered between $67 and $70 per share for Genzyme Corp in what amounts to a friendly acquisition proposal, according to a report in the 3 August 2010 edition of the Wall Street Journal.
Country: United States
Sunday 1 August 2010
Geron Corporation said it has received clearance from the Food and Drug Administration to proceed with a human trial of an embryonic stem cell-based therapy in patients with acute spinal cord injury.
Country: United States
Tuesday September 7 2010
Friday September 3 2010
Friday August 20 2010
Friday August 20 2010
Thursday August 19 2010